real-time news and commentary for investors
Thursday, Oct 18
2012, 7:49 PM
Vivus (VVUS) says it's received the formal opinion from the European Medicines Agency's...
Vivus (VVUS) says it's received the formal opinion from the European Medicines Agency's Committee for Medicinal Products for Human Use. As expected, the CHMP recommended against approval for its obesity treatment Qsiva in the EU. The committee cites concerns over the potential cardiovascular and central nervous system effects associated with long-term use, teratogenic potential, and use by patients for whom the drug is not indicated. VVUS plans to appeal the decision. Shares -2.2% AH.